Status | Study |
Recruiting |
Study Name: Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Condition: Metastatic Angiosarcoma Metastatic Epithelioid Sarcoma Met Date: 2016-12-05 Interventions: Drug: Doxorubicin Given IV |
Recruiting |
Study Name: Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors Condition: Neoplasms Central Nervous System Neoplasms Date: 2015-12-10 Interventions: Drug: LOXO-101 (larotrectinib) Capsules / Liquid Administration |
Recruiting |
Study Name: Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Condition: Sarcoma, Soft Tissue Soft Tissue Sarcoma Undifferentiated Date: 2015-10-12 Interventions: Drug: Dexrazoxane Other Names: |
Recruiting |
Study Name: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Condition: Adult Fibrosarcoma Alveolar Soft Part Sarcoma Date: 2014-07-01 Interventions: Drug: Doxorubicin Hydrochloride |
Recruiting |
Study Name: To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Condition: Neuroblastoma Rhabdomyosarcoma Ewing's Sarcoma Date: 2013-09-27 Interventions: Drug: nab-paclitaxel nab-paclitaxel 100-240 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle |
Active, not recruiting |
Study Name: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Condition: Childhood Alveolar Soft-part Sarcoma Childhood Angiosarcoma Date: 2012-06-06 Interventions: Biological: cixutumumab Given |
Completed |
Study Name: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas Condition: Childhood Alveolar Soft-part Sarcoma Childhood Angiosarcoma Date: 2012-03-27 Interventions: Other: laboratory biomarker analysis Correlative studies |
Recruiting |
Study Name: Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Condition: Adult Alveolar Soft Part Sarcoma Adult Angiosarcoma Adult Date: 2012-02-06 Interventions: Drug: Gemcitabine Hydrochloride |
Completed |
Study Name: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Condition: Adult Alveolar Soft Part Sarcoma Adult Angiosarcoma Adult Date: 2010-06-29 Interventions: Drug: Gamma-Secretase Inhibitor RO4929097 |
Terminated |
Study Name: Phase II Pazopanib Study in Advanced Dermatofibrosarcomas Condition: Dermatofibrosarcomas of DARIER FERRAND(DFSP) Date: 2010-01-28 Interventions: Drug: Pazopanib Administration of pazopanib per os 800mg/ qd during 6 months until stable response accor |